ABCL vs ACAD
AbCellera Biologics Inc. vs ACADIA Pharmaceuticals Inc. — AI-powered side-by-side comparison
ABCL
AbCellera Biologics Inc.
66
Buy
VS
ACAD
ACADIA Pharmaceuticals Inc.
69
Buy
| Metric | ABCL | ACAD |
|---|
| AI Score |
66
|
69
|
| Price |
$9.75
|
$29.41
|
| P/E Ratio |
-18.07×
|
13.07×
|
| ROE |
-15.1%
|
31.9%
|
| Revenue Growth YoY |
—
|
—
|
| Gross Margin |
75.0%
|
91.1%
|
| Debt / Equity |
0.15×
|
0.06×
|
| Dividend Yield |
0.0%
|
0.0%
|
| RSI (14) |
90.0
|
78.4
|
| Beta |
1.191
|
0.845
|
| Expected Upside |
—
|
—
|
AI Committee View
Current Innellis committee reasoning for ABCL versus ACAD.
ACAD leads by 3 points.
ACAD scores 69/100 (Buy) versus ABCL at 66/100 (Buy).
ABCL Committee View
67% agreement
6 analysts
The primary driver is revenue growing 101.3% yoy -- genuine top-line momentum. The main limiting factor is bollinger bandwidth of 77.3% signals elevated volatility. The committee is constructive but not yet at full conviction.
Bull Case
- Price-to-book of 1.1x is a discount to asset value — Value
- Revenue growing 101.3% YoY -- genuine top-line momentum — Growth
- Price structure making higher highs and higher lows — Technical
Bear Case
- ROE of only -17.5% -- cheap may mean cheap for a reason — Value
- RSI at 90 is in overbought territory — Technical
- Price trading above the upper Bollinger Band -- stretched — Technical
ACAD Committee View
83% agreement
6 analysts
The primary driver is revenue growing 47.0% yoy -- genuine top-line momentum. The main limiting factor is bollinger bandwidth of 24.3% signals elevated volatility. The committee is constructive but not yet at full conviction.
Bull Case
- P/E of 13.2 is inexpensive for the broad market — Value
- ROE of 32.4% shows genuine earnings power backing the valuation — Value
- Revenue growing 47.0% YoY -- genuine top-line momentum — Growth
Bear Case
- RSI at 78 is in overbought territory — Technical
- Weekly RSI at 80 -- overbought on the larger timeframe too — Technical
- Bollinger bandwidth of 24.3% signals elevated volatility — Risk